Proactive - Interviews for investors

Itaconix PLC CEO John Shaw takes Proactive's Stephen Gunnion through a trading update that shows record 2023 revenue of $7.9 million, marking a 41% increase from the previous year.

Shaw attributed this success to the company's advancements in the detergent market across North America and Europe, emphasizing cost and performance benefits alongside sustainability. A significant growth of over 89% in European sales, reaching $1 million for the first time, highlighted the potential in the European market, particularly in dish detergents, where Itaconix's low-cost formulations are gaining traction among major retailers and private label brands.

Shaw also noted the company's development in offering plant-based polymers without imposing additional costs on consumers, a strategy dubbed "free green," which promotes sustainability without financial burdens.

The revenue growth stems from a balanced mix of new customer acquisitions and increased recurring revenue from the existing customer base. With a focus on expanding its product portfolio, Shaw mentioned ongoing developments in leather chemicals, paint, and plant-based superabsorbents, aiming to reach a $100 million revenue target in the future.

Looking ahead to 2024, Shaw expressed optimism, citing stabilized costs, minimal disruptions from shipping issues, and the introduction of new brands seeking Itaconix's reformulation expertise, promising continued growth from the momentum built in 2023.

#Itaconix #SustainableDetergents #RevenueGrowth #PlantBasedPolymers #EuropeanMarketExpansion #SustainabilityInRetail #ChemicalInnovation #2023Earnings #FutureGrowth #EcoFriendlyProducts #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Redx Pharma PLC (AIM:REDX) CEO Lisa Anson discusses the enrollment of the first participant in its RXC008 Phase 1 clinical trial in an interview with Proactive's Stephen Gunnion.

RXC008 is a 'first-in-class' ROCK inhibitor, designed to be gut-restricted, targeting fibrostenotic Crohn's disease. This oral molecule inhibits ROCK1 and ROCK2, aiming to avoid systemic side effects like hypertension, and providing targeted action in the gut. This development marks a significant step from laboratory to patient-focused clinical development.

Anson highlighted the unmet need for Crohn's disease treatment, particularly for patients with fibrostenotic complications, where currently no drug treatments are available, leaving surgery as the only option. The next steps for the RXC008 programme include escalating doses in healthy volunteers, with plans to move into patient trials towards the end of the year.

Additionally, Anson mentioned Redx Pharma's broader portfolio, noting that RXC008 is the sixth molecule from Redx to enter clinical trials, showcasing the company's drug discovery prowess. Other key developments include the Phase 2 trials of RXC007 for lung fibrosis and RXC004 for cancer, both expected to report data this year.

#RedxPharma #ClinicalTrials #CrohnsDisease #DrugDevelopment #HealthcareInnovation #MedicalResearch #Biotech #RXC008 #FibrostenoticCrohns #Pharmaceuticals

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

AFC Energy PLC (AIM:AFC, OTC:AFGYF) CEO Adam Bond joins Proactive's Stephen Gunnion with details of its latest advancements in ammonia cracker reactor technology.

After launching its first modular scalable ammonia cracker at COP28 last year, Bond said AFC Energy had achieved world-class efficiency levels in ammonia cracking technology well ahead of schedule. This development is pivotal for the sustainable production and transportation of hydrogen.

AFC Energy's approach proposes manufacturing hydrogen in regions with low energy costs, like the Middle East, and transporting it as ammonia to areas where energy is more expensive, such as the UK and Europe. The latest advancement in the technology facilitates a 33% reduction in electrical power consumption compared to the 2023 design, with expectations to reduce energy usage to below 10 kilowatt-hours per kilogram, positioning AFC Energy as a leader in the market.

The company is on track to further reduce energy consumption within the next 12 months.

Discussions and visits from major global producers of green and blue ammonia indicate strong commercial interest, with revenue expected from 2025. AFC Energy is scaling up its next-generation technology and aims to finalize the commercial module size, resembling a large washing machine, within this calendar year.

#AFCenergy #AmmoniaCracking #GreenHydrogen #SustainableEnergy #RenewableEnergy #HydrogenTransportation #EnergyEfficiency #Commercialization2025 #TechnologyAdvancement #FuelCellTechnology #proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The FTSE 100 made another losing start after a mixed day for US markets and losses overnight in Asia.

London’s blue-chip index was down nineteen points in early trades at 7,663 with a slew of company updates also affecting the mood.

Wealth manager St James Place slumped into a loss after taking a £426 million provision for potential refunds over its handling of complaints, which soared in the second half of 2023.

Retailer Halfords issued a profit warning as it said the weather, weak consumer confidence and a tough cycling market had hit footfall in its stores.

Aston Martin Lagonda did better and cut its losses slightly as average selling prices for its luxury supercars hit record levels.

Housebuilder Taylor Wimpey also beat forecasts and said the market outlook is improving even though revenues fell by 20% and profits by 48% in 2023.

#proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Pyxis Tankers Inc (NASDAQ:PXS) chairman and CEO Valentios (Eddie) Valentis, provides an update on the company's performance and future plans in an interview with Proactive's Stephen Gunnion.

For the nine months ending September 2023, the company reported net revenues of $32.2 million and an adjusted EBITDA of approximately $15 million, with fully diluted earnings per share at $1.21.

The average daily time charter equivalent for the MRs in Q4 increased to about $30,500 per day, with bookings for Q1 2024 at approximately $29,200 for 75% of available days. Pyxis Tankers maintains a solid balance sheet and liquidity, having completed the sale of the 2015-built MR at a record price, realising a gain of over $17 million.

The fleet currently includes three eco-efficient MR tankers with an average age of approximately nine years and has expanded into the dry bulk sector with the acquisition of three vessels, bringing the total fleet to five.

The company is exploring further acquisitions, particularly in the eco-friendly dry bulk space, and remains positive about the market conditions for both tanker and dry bulk sectors, despite geopolitical tensions and weather-related disruptions.

Pyxis Tankers has repurchased 7% of its outstanding float and holds approximately 400,000 shares of Series A convertible preferred stock, trading under the symbol PXS AP.

#ProactiveInvestors #PyxisTankers #ShippingIndustry #TankerMarket #DryBulkShipping #FinancialPerformance #FleetExpansion #EcoEfficientVessels #MarketOutlook #StockRepurchase #UndervaluedShares #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Hydrogen Utopia International PLC (LSE:HUI, OTCQB:HUIPF) CEO Aleksandra Binkowska discussed the company's reverse takeover of Helmond Holding Group, which is in the process of changing its name to Essential Energy Holding Group, emphasizing the transformational nature of the acquisition.

Helmond operates in the renewable energy sector, focusing on biofuels and bioenergy, with a strong presence in Argentina. The company aims to dominate the bioenergy market and contribute to global decarbonization efforts.

With a turnover of $350 million and a conservative profit estimate of $40 million, Helmond's financial health is robust. Binkowska highlighted the strategic fit between the two companies, noting Helmond's established bioethanol business and recognition of hydrogen as the future of energy.

The deal involves a reverse takeover, valuing the combined entity at £500 million. Shareholders of Hydrogen Utopia will receive both cash and shares in the new company, with additional shares contingent on the success of the technology. Binkowska will remain on the board to ensure the technology's implementation, benefiting from Helmond's resources, including land, utilities, and permits. The deal's completion is anticipated by May or June, pending regulatory approval and due diligence.

#HydrogenUtopia #RenewableEnergy #Biofuels #CleanTech #EnergyTransition #SustainableInvesting #GreenEnergy #Decarbonisation #HydrogenEnergy #EnergyInnovation #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Powerhouse Energy Group PLC (AIM:PHE) CEO Paul Emmitt tells Proactive's Stephen Gunnion that a five-year framework agreement with National Hydrogen of Australia is a significant milestone for the company and an endorsement of its proprietary waste-to-energy technology.

Emmitt said the two companies have collaborated on feasibility and engineering assessments over the past two and a half years, with intense due diligence conducted on the technology. This collaboration has led to the technology being shortlisted by a major Japanese entity, further validating Powerhouse Energy's solutions.

The agreement, initially expected to cover projects in Australia, has expanded to include Hong Kong, Italy, and Switzerland, thanks to undisclosed partnering entities. This deal is notable for requiring no upfront funding from Powerhouse Energy; instead, it operates on a fully funded front-end engineering design model that transitions into a licensing and royalty agreement. This shift significantly reduces financial burdens on Powerhouse and secures its involvement throughout project development and execution phases.

Under the agreement, Powerhouse will develop the entirety of the facilities for each project, from feedstock processing to hydrogen export, leveraging its intellectual property in sim gas control. This involves close collaboration with yet-to-be-selected EPC contractors and a guarantee of the output quality of sim gas from the processing kiln.

Emmitt highlighted the partnership's potential to set new benchmarks in the hydrogen industry, emphasizing the importance of integrated waste processing and hydrogen distribution networks.

#PowerhouseEnergy #RenewableEnergy #HydrogenFuel #SustainableTechnology #WasteToEnergy #CleanEnergy #GreenHydrogen #EnergyInnovation #EnvironmentalSustainability #TechAdvancement #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Race Oncology Ltd (ASX:RAC) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of bisantrene, which is undergoing Phase II trials specifically for Acute Myeloid Leukemia. The clinical-stage biopharmaceutical company develops drugs designed to treat cancer, but is unique in that its novel approach treats the cancer, while protecting the heart. Race has had a strong half of the financial year, executing an exclusive licensing agreement with City of Hope and entering an agreement with Ardena Holding NV, to provide additional current Good Manufacturing Practice (cGMP). The company is now focused on hitting several milestones through 2024.

#ProactiveInvestors #RaceOncology #ASX #Biotech #Bisantrene #AcuteMyeloidLeukemia

Tennant Minerals Ltd (ASX:TMS) CEO Vincent Algar joins Proactive’s Jonathan Jackson to share insights into the company and its recent activities at Bluebird prospect within the Barkly Copper-Gold Project in the Northern Territory. The project is about 45 kilometres east of the major copper-gold mineral field of Tennant Creek and the company is focused on the expansion and delineation of the greenfield Bluebird high-grade copper-gold discovery. Algar takes us through recent work carried out at Bluebird, including the latest results and why they are significant for the company and its stakeholders. The results pave the way for a forthcoming drilling program aimed at further exploration as Tennant looks to establish a maiden mineral resource. Finally, Algar outlines the investment case for Tennant Minerals, highlighting the potential benefits for investors and the strategic value of the company's projects.

#ProactiveInvestors #TennantMinerals #ASX #Copper #Gold #TennantCreek

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Actinogen Medical Ltd (ASX:ACW) CEO Steven Gourlay joins Jonathan Jackson in the Proactive studio to discuss the company's focus on neuro therapeutics and to review the highlights from the first half of the financial year. Steven brings a wealth of experience from the biotech industry, including as founding chief medical officer of Principia Biopharma Inc, which sold to Sanofi for $3.7 billion in 2020. Gourlay details the company’s work in developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. The company is developing its lead compound, Xanamem®, a new therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. He takes us through current clinical trials, the company’s strong financial position and outlines the strategic priorities for the next 18 months, giving investors an idea of what to expect moving forward.

#ProactiveInvestors #ActinogenMedical #ASX #biotech #neurology #Xanamem

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews